Table A2.
Patient Characteristics (N = 21)
| Characteristic | Patients (N = 21) |
|
|---|---|---|
| No. of Patients Affected | Total No. of Patients Involved | |
| Time from diagnosis, months | ||
| Median | 26 | |
| Range | 6 to 80 | |
| Age at diagnosis, years* | ||
| Median | 3.9 | |
| Range | 1.7 to 11.2 | |
| Age at entry, years | ||
| Median | 6.5 | |
| Range | 2.8 to 13.5 | |
| Sex | ||
| Male | 9 | |
| Female | 12 | |
| MYCN amplification | 4 | 17 |
| Disease status | ||
| Primary refractory | 5 | |
| Relapsed or progressive | 16 | |
| Prior therapy | ||
| Median | 3 | |
| Range | 2 to 11 | |
| Prior ASCR | 12 | |
| Prior radiotherapy | 16 | |
| GFR > 100 mL/min/1.73 m2 | 17 | 21 |
| Disease sites | ||
| Bone | 19 | |
| Bone marrow | 13 | |
| Soft tissue | 12 | |
| Elevated urine VMA and/or HVA | 6 | 20 |
Abbreviations: ASCR, autologous stem-cell rescue; GFR, glomerular filtration rate; VMA, vanillylmandelic acid; HVA, homovanillic acid.
*
Only one patient at diagnosis and two patients at time on study were older than 10 years of age.